Inhibitors of the plasmodial surface anion channel as antimalarials
Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 to R 7 are as described herein.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and
(i) a compound selected from:
wherein the pharmaceutical composition is a formulation suitable for oral administration selected from capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the compound as solid or as granules.
2. The pharmaceutical composition of claim 1 , wherein the compound is:
3. The pharmaceutical composition of claim 1 , wherein the compound is:
4. The pharmaceutical composition of claim 1 , wherein the compound is:
5. The pharmaceutical composition of claim 1 , wherein the compound is:
6. The pharmaceutical composition of claim 1 , wherein the compound is:
7. The pharmaceutical composition of claim 1 , wherein the compound is:
8. The pharmaceutical composition of claim 1 , wherein the compound is:
9. The pharmaceutical composition of claim 1 , wherein the compound is: